Figure 2.

Clinical status at baseline, day 15, and day 29 in the intention-to-treat population, according to treatment group and COVID-19 severity at random assignment

24 participants (12 in each group) were assessed as having moderate disease at random assignment but had their disease severity revised to severe at the baseline evaluation. 21 participants (eight in the remdesivir group, 13 in the control group) were assessed as having severe disease at random assignment but had their disease severity revised to moderate at the baseline evaluation. ECMO=extracorporeal membrane oxygenation.